One could say the holy grail of diagnostic medicine is simple, low-cost point-of-care technologies that can be implemented in the home or in laboratories outside of the high-tech infrastructure we have come to know in the developed world. In a race in which there have been only a few winners over the last few decades, one technology stands above them all: personal glucose meters (PGMs).
PGMs have been around for more than 40 years and are universally used for intensive diabetes control. Much time and money have gone into making these tools robust and reliable, according to many researchers.
Aware of this serious vetting process, chemistry professor Yi Lu and his postdoctoral fellow Yu Xiang at the University of Illinois at Urbana-Champaign had an idea: What if they take the PGM, capitalize on its functionality, and use it to test for analytes other than glucose?
Other laboratories have attempted the feat, but Lu and Xiang tried something different: They wanted to use the PGM to detect for nonglucose analytes without changing the device in any way.
We sat down with Lu to chat about the new technology and how the team has already made leaps in the technology's functionality.
Yi Lu

Why Is This Invention Important?
After years of perfecting technologies that allowed in vitro visualization with colorimetric assays, Lu wanted to try something different. "It was nice, but we still needed a device to see the fluorescence," says Lu. He and Xiang wondered if there was a way to visualize other analytes without a chemical analyzer. That is when they turned to PGMs. "We made a point not to make any change to the meter," says Lu. By playing with the solution and not the device, the duo was able to create a system for testing nonglucose targets, such as toxic metal ions, DNA, proteins, biological cofactors, and recreational drugs.
To use the system in the clinical laboratory, a clinician would get from Lu a small vial meant to test for certain target molecules. The researcher would add a solution of the sample to the vial, let it sit, attach a glucose strip, and then make the reading. "You add liquid to the vial, shake and bake, and wait 2 minutes for the glucose meter to read the sample," says Lu.
The various analyte scans are all built on the same elegant formula: A chemical reaction set in motion by the presence of a target molecule produces glucose. The glucose is thus a means to indirectly measure the presence of a nonglucose analyte.
"This technique is incredibly innovative and thoughtful," says Robert Mittendorf, an emergency physician and former vice president of marketing and business development at Hansen Medical and who was not involved in the research. "As an emergency physician, I
would enjoy having a portable quantitative biomarker laboratory in my pocket, especially if I were working in a place with limited infrastructure and resources."
How Does It Work?
Lu wanted 2 features in his diagnostic device-the ability to amplify a desired analyte and the ability to quantify it with a PGM. The dynamic range of a PGM is 10.8 -595 mg/dL (0.6 -33 mmol/L) glucose, whereas the concentrations of most analytes Lu wanted to measure were in the micromolar or nanomolar range. Lu's trick to amplification lay in using the enzyme invertase, which has a high turnover number in converting sucrose into fructose and glucose. In the reactions that Lu engineers, invertase is released in a known reaction to the target and proceeds to hydrolyze sucrose to glucose in a predictable way. Two features here are notable. The first is that as little as a nanomole of target liberates enough invertase to convert on the order of millimoles of sucrose into glucose. The second is that a PGM recognizes only glucose, giving an accurate readout of the reaction's end point.
Lu engineered invertase conjugates with functional DNAs (aptamers or DNAzymes) or antibodies to detect target analytes such as cocaine or prostate-specific antigen, respectively (Fig. 1) . The conjugates are immobilized on magnetic beads, which are then mixed with the patient's sample. The mixture is then washed and magnetically separated. In the case of functional-DNA conjugates, the target induces the release of the DNA-invertase conjugate that converts the sucrose in solution to the glucose that the PGM quantifies.
Lu has recently demonstrated the use of antibodies in his setup for quantifying targets via well-established antibody-antigen interactions. Multiple-epitope targets, such as prostate-specific antigen, are quantified with sandwich assays, whereas smaller, monoepitopic targets, such as ochratoxin A, are quantified with competitive assays. In a sandwich assay, the amount of bound invertase is directly related to the target concentration, whereas the invertase activity in a competitive assay is related, depending on the design, directly or inversely to the concentration of the target. For all designs, invertase (and thereby the target's concentration) is measured through the amount of glucose quantified by the PGM.
Where Can This Technology Fit in the Clinical Laboratory?
Lu's dream is to walk into a pharmacy store and see PGMs shelved next to strips that read not only for glucose but also for "cancer, AIDS, and cardiovascular disease," says Lu. "Obviously we have a long way to go."
One limitation is that the system is able to read only analytes in solution, so for researchers like environmental scientists, who might want to analyze toxic gases, the device is a nonstarter. Another major critique, according to Lu, has been that the number and classes of molecules read by the device have been limited; however, a recent report by Lu's team published in Analytical Chemistry (1 ) shows that anyone using a clinical analyzer can adopt this technology for pointof-care diagnostics. "This latest paper says you can use any antibody anybody has ever developed," says Lu. "To me, that's really, really huge."
The potential is not lost on Mittendorf, the emergency room physician. "If in fact the assay could be used on a variety of different antibodies, it obviously opens up a large number of potential applications," he says. "I can imagine that for patients with lifethreatening infections, we might test in the care setting for specific types of bacteria or viruses to more rapidly target antibiotics or care. I can also imagine a more continuous view of particular tests that we currently repeat at regular intervals, like troponins or lactates."
Mittendorf suggests he would like to see a future version of the device that could be used to predict the onset of disease or to monitor treatment. "If a clinician could remotely use this information to modulate current therapies in an attempt to reduce the likelihood of ED visit or admission, the cost savings could be enormous."
In the end, Lu sees his team's sensor-and each improvement on it-as just one step toward a diverse, cost-effective device useful to clinicians anywhere in the world. "We're not trying to replace clinical analyzers; we're trying to make a complementary tool." Reprinted with permission from (1 ). ©2012 American Chemical Society.
